Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM

Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma

Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone

Bladder cancer updates from the second half of 2024

EMUC 2024: Optimising strategies in mHSPC and mCRPC

SIOG 2024: Updates in haematology

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients

Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM

Understanding the remaining unmet needs in a post ASCT NDMM setting